Bionano genomics news.

An Accounting Trick Not to Neglect. Shareholders of Bionano Genomics have been diluted in the past year, with total shares outstanding growing by 6.4%.. This is the base news for valuation ...Company profile page for Bionano Genomics Inc including stock price, company news, press releases, executives, board members, and contact information9 Mei 2023 ... News Release Details. « Back. Bionano Reports First Quarter 2023 ... Bionano Genomics is a provider of genome analysis solutions that can ...SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2023. Business Updates Since the End of Q3 2023 . Completed an $80.0 million registered offering and concurrent private placement.Bionano Genomics SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company …

A list of the latest Bionano Genomics Inc News - BNGO Stock News, Press Releases, Earnings Report, Financial Disclosures, Offerings, Acquisitions.SAN DIEGO, October 12, 2021 (GLOBE NEWSWIRE) - Bionano Genomics, Inc. (BNGO) today announced that it has entered into a definitive agreement to acquire BioDiscovery, Inc., a leading software company with best-in-class solutions for analysis, interpretation and reporting of genomics data.

Bionano Genomics. April 24, 2023 at 9:54 AM · 8 min read. Bionano Genomics. Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase ...

Bionano Genomics SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication …SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano’s optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories’ first …EF Hutton has initiated coverage of Bionano Genomics Inc (NASDAQ:BNGO) with a Buy rating and a price target of $1.75.; The analyst says Bionano Genomics's optical genome mapping (OGM) platform is ...SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that its Chinese OEM partner, Ecobono, a distribution …

In its recent quarterly earnings release, Bionano Genomics reported $7.22 million in revenue, a 55% increase. But in absolute terms, there is plenty of market share for grabs at the moment.

Bionano Reports First Quarter 2023 Results and Highlights Recent Business Progress. Q1 2023 revenue was $7.4 million, which represents a 30% increase over Q1 2022. Installed base of 259 Saphyr ...

Aug 1, 2023 · SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023. Bionano Genomics Q3 Revenues Grow 29 Percent. In line with its previous estimate, the San Diego-based optical genome mapping company reported $9.3 million in revenues, compared to $7.2 million a year ago.Bionano Genomics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies. News Coverage …Find the latest Bionano Genomics, Inc. (BNGO) stock quote, history, news and other vital information to help you with your stock trading and investing.Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.Headline. After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO) finance.yahoo.com - November 17 at 2:20 PM. Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and Ascendis Pharma (ASND) markets.businessinsider.com - November 16 at 11:51 PM.

News Release Details « Back. Bionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies. Feb 22, 2023 | PDF Version. ... About Bionano Genomics. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers …About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business ...Q2 2023 revenue was $8.7 million , which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023 , which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023 , which represents a 108% increase over theBionano Genomics Inc. Investors: Company Investigated by the Portnoy Law Firm. April 17, 2023 14:49 ET ... On this news the Company’s stock fell over 20% during intraday trading.Apr 13, 2023 · The current analyst consensus has Bionano Genomics, Inc. losing around 45 cents a share in FY2023 as sales rise nearly 30% to $35.7 million. Revenue growth is projected to accelerate by over 70% ... The market expects Bionano Genomics, Inc. (BNGO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2022.

Bionano Genomics. SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a …Third quarter 2023 non-GAAP operating expense was $31.8 million, compared to $26.3 million in the third quarter of 2022 and $34.6 million in the second quarter of 2023. Third quarter 2023 non-GAAP ...

Automate Data Display for Powerful Insights. VIA software amplifies the story of your data by automatically generating powerful visualizations for enhanced variant contextualization across multiple variant types happening in the same genomic region. VIA allows you to drill down to single chromosome, gene, and nucleotide levels for deeper analysis. Nov 3, 2022 · SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today reported financial results for the third quarter ended September 30, 2022. The current analyst consensus has Bionano Genomics, Inc. losing around 45 cents a share in FY2023 as sales rise nearly 30% to $35.7 million. Revenue growth is projected to accelerate by over 70% ...Oct 11, 2023 · SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, a... Bionano Genomics (BNGO-8.48%) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Here's ...Let’s get ready to reconnect in Torino, Italy – stop by our booth #54! We’re on a mission to change the way the world sees the genome with genome mapping systems, nucleic acid purification solutions, analysis software, and clinical testing services. Come explore the genomic variation continuum, from SNVs to whole chromosomes, through our ...Saphyr®, Bionano's third-generation optical mapping solution, provides what's missing in genome research – rapid, high-throughput, long-range genome mapping ...4 Agu 2023 ... SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock ...Good afternoon, everyone. Welcome to the Bionano Genomics first quarter 2023 financial results conference call. Leading the call today is Dr. Erik Holmlin, CEO of Bionano; joined by Chris Stewart ...

Oct 11, 2023 · SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, a...

Get the latest BioNano Genomics Inc (BNGO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.Price Target and Analysts Recommendations: Three buys and one hold from analysts covering the stock. Oppenheimer's analyst Kevin DeGeeter maintained a Buy rating on February 2021, setting a price target of $15 which is approximately 75% above today´s share price of $8.59 (03/18/2021). DeGeeter expects BioNano Genomics Inc to post earnings …About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.Bionano Genomics (BNGO-8.48%) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Here's ...About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business ...21 Jun 2018 ... The company makes a genome mapping system called Irys®, which offers highresolution, single-molecule analysis of long strands of DNA. BioNano ...Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2023 Earnings Call Transcript Reported EPS is $-1 EPS, expectations were $-0.75. Operator: Good day, and welcome to the …Get the latest BioNano Genomics Inc (BNGO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Jan 10, 2023 · SAN DIEGO , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. (BNGO) today announced its 2023 Symposium, which is the quintessential event for the optical genome mapping (OGM) community to present its progress to the world. It will feature four consecutive days of OGM presentations SAN DIEGO , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. (BNGO) today announced its 2023 Symposium, which is the quintessential event for the optical genome mapping (OGM) community to present its progress to the world. It will feature four consecutive days of OGM presentationsIn 2022, BNGO's revenue was $27.80 million, an increase of 54.62% compared to the previous year's $17.98 million. Losses were -$132.60 million, 83.1% more than in 2021. According to 4 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is $46.67, which is an increase of 2,853.80% from the latest …

A big change in the C-suite was behind the steep fall in Bionano Genomics ' ( BNGO -7.27%) share price on Monday. Following the biotech's announcement that its CFO is stepping down, investors ...Dec 31, 2022 · SAN DIEGO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported certain unaudited preliminary financial and commercial highlights for the fourth quarter and fiscal year ended December 31, 2022. The Company’s full results for the fourth quarter and the fiscal year ended December 31, 2022 are not yet available. SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families.The study authors conducted a comprehensive analysis of samples from …Instagram:https://instagram. jnj credobuy oxyk1 filingnasdaq urbn About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. fcelstockis now a good time to invest in real estate Bionano Genomics, Inc. +1 (858) 888-7610. [email protected]. Investor Relations: Amy Conrad. Juniper Point. +1 (858) 366-3243. [email protected]. Bionano CEO and president Dr. Erik Holmlin ... worst months for stock market Automate Data Display for Powerful Insights. VIA software amplifies the story of your data by automatically generating powerful visualizations for enhanced variant contextualization across multiple variant types happening in the same genomic region. VIA allows you to drill down to single chromosome, gene, and nucleotide levels for deeper analysis. SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families. The study authors conducted a comprehensive analysis of samples from ...